Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2005
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AX04
|
| gptkbp:CASNumber |
191732-72-6
|
| gptkbp:chemicalFormula |
C13H13N3O3
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:controlledSubstanceSchedule |
no
|
| gptkbp:developedBy |
gptkb:Celgene
|
| gptkbp:genericName |
gptkb:lenalidomide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Revlimid
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:mechanismOfAction |
anti-angiogenic
immunomodulatory |
| gptkbp:patentExpired |
2022
|
| gptkbp:pregnancyCategory |
X
|
| gptkbp:relatedTo |
gptkb:thalidomide
|
| gptkbp:riskFactor |
teratogenicity
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue rash neutropenia thrombocytopenia |
| gptkbp:usedFor |
gptkb:mantle_cell_lymphoma
multiple myeloma myelodysplastic syndromes |
| gptkbp:bfsParent |
gptkb:Celgene
gptkb:Bristol_Myers_Squibb gptkb:BMS gptkb:百时美施贵宝 gptkb:Bristol-Myers_Squibb |
| gptkbp:bfsLayer |
6
|